Details for New Drug Application (NDA): 021301
The generic ingredient in LEVOXYL is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
Summary for 021301
| Tradename: | LEVOXYL |
| Applicant: | King Pharms |
| Ingredient: | levothyroxine sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 021301
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301 | NDA | Pfizer Laboratories Div Pfizer Inc | 60793-850 | 60793-850-01 | 100 TABLET in 1 BOTTLE (60793-850-01) |
| LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301 | NDA | Pfizer Laboratories Div Pfizer Inc | 60793-850 | 60793-850-10 | 1000 TABLET in 1 BOTTLE (60793-850-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | ||||
| Approval Date: | May 25, 2001 | TE: | AB1,AB3 | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | ||||
| Approval Date: | May 25, 2001 | TE: | AB1,AB3 | RLD: | Yes | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | ||||
| Approval Date: | May 25, 2001 | TE: | AB1,AB3 | RLD: | Yes | ||||
Expired US Patents for NDA 021301
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-004 | May 25, 2001 | 6,555,581 | ⤷ Start Trial |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-009 | May 25, 2001 | 7,067,148 | ⤷ Start Trial |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-007 | May 25, 2001 | 7,101,569 | ⤷ Start Trial |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-006 | May 25, 2001 | 7,101,569 | ⤷ Start Trial |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-002 | May 25, 2001 | 6,555,581 | ⤷ Start Trial |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-003 | May 25, 2001 | 7,067,148 | ⤷ Start Trial |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-008 | May 25, 2001 | 7,101,569 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
